Core Viewpoint - The A-share market for pharmaceutical retail stocks experienced a collective rise, driven by new government measures aimed at enhancing pharmaceutical services and encouraging retail drug sales [1] Group 1: Market Performance - Pharmaceutical retail stocks such as Renmin Tongtai and Yifeng Pharmacy hit the daily limit up, while Luyuan Pharmaceutical rose over 7%, Daclin increased over 6%, and Jiuzhoutong gained over 5% [1] - Other notable performers included Zhongyao Holdings, Yaoyigou, Haiwang Biological, Hefuchina, and Shuyupingmin, all rising over 4% [1] Group 2: Government Measures - The Ministry of Commerce and nine other departments issued a document proposing improvements in pharmaceutical services, enhancing pharmacy service capabilities, and promoting prescription circulation to improve the purchasing experience [1] - Measures include optimizing outpatient service coordination for designated retail pharmacies and encouraging retail drug companies to participate in centralized drug procurement [1] - The government is promoting horizontal mergers and acquisitions among retail drug companies and encouraging the sale of innovative drugs and reference preparations through retail channels [1] - There is an emphasis on encouraging e-pharmacy platforms to open data interfaces and strengthen the monitoring of price linkages between online and offline drug retail prices and provincial procurement platform prices [1]

Group 1 - The core viewpoint of the article highlights a collective rise in A-share pharmaceutical commercial stocks, driven by government initiatives to enhance pharmaceutical services and retail drug sales [1] - The Ministry of Commerce and nine other departments issued a document proposing measures to improve pharmaceutical services, enhance pharmacy service capabilities, and promote prescription circulation to improve the purchasing experience [1] - The document encourages pharmaceutical retail companies to engage in horizontal mergers and acquisitions, and to innovate in drug sales channels, including the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2 - Notable stock performances include: - Renmin Tongtai (人民同泰) with a rise of 10.04% and a total market value of 72.43 billion [2] - Yifeng Pharmacy (益丰药房) increasing by 10.02% with a market cap of 301 billion [2] - Luyuan Pharmaceutical (鹭燕医药) up by 7.76% with a market value of 70.13 billion [2] - Dacelin (大参林) rising by 6.63% with a market cap of 242 billion [2] - Jiuzhoutong (九州通) increasing by 5.27% with a market value of 282 billion [2] - Other companies showing significant gains include Zhongyao Holdings (重药控股) up by 4.89%, Yaoyigou (药易购) up by 4.42%, and Haiwang Biological (海王生物) up by 4.41% [2]

Core Viewpoint - The retail pharmacy sector experienced a significant rise in stock prices following the release of a government policy aimed at promoting high-quality development in the pharmaceutical retail industry [1] Group 1: Policy Impact - On January 22, the Ministry of Commerce and nine other departments issued guidelines to encourage horizontal mergers and acquisitions in the pharmaceutical retail sector [1] - The policy aims to optimize the business environment for retail pharmacies, including streamlining the application process for drug operating licenses for consolidated chain or standalone pharmacies [1] - It promotes the integration of wholesale and retail operations to enhance supply chain efficiency and reduce operational costs through shared logistics resources and collaborative quality management systems [1] Group 2: Market Outlook - According to Guojin Securities, leading compliant pharmacy chains are expected to benefit first from the ongoing regulatory push for industry standardization [1] - Companies that have proactively adjusted their store operations are projected to see a marginal recovery in revenue by the third quarter of 2025 [1] - Some leading companies are beginning to explore non-pharmaceutical product offerings, which could become a significant source of profit if they exceed expectations in performance [1]

Core Viewpoint - The pharmaceutical commercial sector experienced a slight increase of 0.39% on January 19, with significant contributions from stocks like Dajia Weikang, which led the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4114.0, up by 0.29%, while the Shenzhen Component Index closed at 14294.05, up by 0.09% [1] - Dajia Weikang (301126) led the sector with a closing price of 13.91, reflecting a rise of 6.43% and a trading volume of 162,500 shares, amounting to a transaction value of 220 million yuan [1] - Other notable performers included Dacianlin (603233) with a 4.37% increase, Guofang Co. (600538) up by 3.27%, and Yifeng Pharmacy (603939) rising by 2.55% [1] Group 2: Fund Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 436 million yuan from institutional investors, while retail investors contributed a net inflow of 486 million yuan [2] - The individual stock fund flow indicated that Ruikang Pharmaceutical (002589) had a net inflow of 19.77 million yuan from institutional investors, while it faced a net outflow of 17.52 million yuan from retail investors [3] - Dajia Weikang (301126) also experienced a net inflow of 13.40 million yuan from institutional investors, despite a net outflow of 15.06 million yuan from retail investors [3]

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

Market Performance - The pharmaceutical commercial sector increased by 1.32% on January 9, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] Top Gainers - RunDa Medical (603108) closed at 17.94, up 9.99% with a trading volume of 846,200 shares [1] - Huaren Health (301408) closed at 22.17, up 9.97% with a trading volume of 627,800 shares [1] - Shangyu Pingmin (301017) closed at 17.24, up 7.75% with a trading volume of 336,500 shares [1] Other Notable Stocks - Zhongyao Holdings (000950) closed at 6.31, up 5.87% with a trading volume of 1,147,000 shares [1] - Saily Medical (603716) closed at 27.83, up 4.39% with a trading volume of 783,100 shares [1] Market Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 122 million yuan from institutional investors and 174 million yuan from speculative funds, while retail investors saw a net inflow of 296 million yuan [2] - The trading volume and turnover for various stocks indicate a mixed sentiment among different investor categories [2] Individual Stock Fund Flow - RunDa Medical had a net inflow of 2.30 billion yuan from institutional investors, while it faced a net outflow of 1.36 billion yuan from speculative funds [3] - Zhongyao Holdings saw a net inflow of 61.04 million yuan from institutional investors, with a net outflow of 62.93 million yuan from retail investors [3] - The overall fund flow indicates varying levels of confidence among different investor types in the pharmaceutical sector [3]

证券代码：600829 证券简称：人民同泰 公告编号：临 2026-001 哈药集团人民同泰医药股份有限公司 关于公司 2026 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否需要提交股东会审议：是 在董事会召开前，公司董事会审计委员会 2026 年第一次会议审 议通过了《关于公司 2026 年度日常关联交易预计的议案》，关联董事 尹世炜先生回避表决，董事会审计委员会同意将该议案提交公司董事 会审议。公司独立董事专门会议 2026 年第一次会议，审议通过了《关 于公司 2026 年度日常关联交易预计的议案》，全体独立董事同意将该 议案提交公司董事会审议。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 哈药集团人民同泰医药股份有限公司（以下简称"公司"）第十 一届董事会第五次会议通知于 2025 年 12 月 31 日以书面及电子邮件 方式向全体董事发出，会议于 2026 年 1 月 9 日以通讯会议方式召开， 审议通过了《关于公司 2026 年度日常关联交易预计的 ...

Market Performance - The pharmaceutical commercial sector increased by 0.97% compared to the previous trading day, with Luyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Key stocks in the pharmaceutical commercial sector showed significant gains, with Yinghe Pharmaceutical rising by 10.02% to a closing price of 22.72, and Jiashitang also increasing by 10.00% to 17.38 [1] - Other notable performers included Saili Medical and Renmin Tongtai, both showing increases of 10.00% and 2.64% respectively [1] Trading Volume and Value - Yinghe Pharmaceutical had a trading volume of 636,200 shares, resulting in a transaction value of approximately 1.396 billion yuan [1] - Jiashitang and Saili Medical also reported substantial trading volumes of 119,600 and 74,200 shares, with transaction values of around 208 million yuan and 185 million yuan respectively [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 188 million yuan from institutional investors and 252 million yuan from speculative funds, while retail investors saw a net inflow of 439 million yuan [2] - The capital flow data indicates varying investor sentiment, with retail investors showing a positive trend in the sector [2] Stock-Specific Capital Flow - Luyuan Pharmaceutical had a net inflow from retail investors of approximately 1.02 billion yuan, despite a net outflow from institutional and speculative investors [3] - Jiashitang and Saili Medical also experienced mixed capital flows, with Jiashitang seeing a net inflow of 84.96 million yuan from institutional investors [3]

Group 1: Market Performance - Heilongjiang Province's capital market index rose by 4.82% in December 2025, outperforming the Shanghai Composite Index and Shenzhen Component Index, but slightly underperforming the ChiNext Index[19] - In the last three trading days of December, the Heilongjiang index experienced a minor decline of 0.38%, attributed to normal market adjustments[22] - The overall performance of listed companies in Heilongjiang was weak, with 24 companies reporting negative returns and only 15 achieving positive returns[25] Group 2: Key Company Highlights - Guanglian Aviation saw the highest increase at 112.11%, followed by Aerospace Science and Technology (+51.11%), New Light Optoelectronics (+41.21%), Dapeng Industry (+36.05%), and China First Heavy Industries (+32.56%)[25] - Notably, 12 companies experienced declines exceeding 5%, with four companies, including Renmin Tongtai (-14.68%) and Fuerjia (-14.51%), seeing declines over 10%[25] Group 3: Economic and Policy Developments - Heilongjiang Airport Group achieved record transportation figures in 2025, with 205,000 flight takeoffs and landings, 29.064 million passengers, and 154,000 tons of cargo, marking year-on-year increases of 1%, 1.2%, and 4.8% respectively[3] - The province announced a new consumption upgrade policy on December 31, 2025, offering subsidies for replacing old vehicles and purchasing energy-efficient appliances, with maximum subsidies of 20,000 yuan for new energy vehicles and 1,500 yuan for energy-efficient appliances[10] Group 4: Industry Trends - The establishment of the Huagong Technology Intelligent Manufacturing Northern Headquarters in Harbin, with an investment of 100 million yuan, aims to drive the integration of industry and technology, focusing on the production of intelligent laser weeding robots[12] - The manufacturing sector's PMI rose to 50.1% in December, indicating a return to expansion after eight months, with significant improvements in production and new orders[27]

Group 1 - The report highlights that the Heilongjiang Airport Group achieved record transportation volumes in 2025, with 205,000 flight takeoffs and landings, 29.064 million passengers, and 154,000 tons of cargo, representing year-on-year growth of 1%, 1.2%, and 4.8% respectively [3][9] - The group has expanded its domestic and international routes to 363, connecting 112 cities, and is promoting the integration of "aviation + tourism" to enhance local economic development [3][9] - The report notes the launch of a new consumption upgrade policy in Heilongjiang, providing subsidies for replacing old vehicles and purchasing energy-efficient appliances, aimed at stimulating consumer spending [5][10] Group 2 - The report indicates that the Heilongjiang sector index rose by 4.82% in December 2025, outperforming the Shanghai and Shenzhen indices, with a notable divergence in the performance of listed companies [19][25] - Five companies in the province saw significant gains, with Guanglian Aviation leading at 112.11%, followed by Aerospace Science and Technology (+51.11%) and New Light Optoelectronics (+41.21%) [25][26] - Conversely, 24 companies reported negative returns, with four companies experiencing declines exceeding 10%, including Renmin Tongtai (-14.68%) and Fuerjia (-14.51%) [25][26] Group 3 - The report emphasizes the integration of industry and technology, citing the launch of the Huagong Technology Intelligent Manufacturing Northern Headquarters in Harbin, which focuses on the development of intelligent laser weeding robots [12][13] - The project, with an investment of 100 million yuan and an annual production capacity of 200 units, aligns with the "storing grain in the ground and technology" strategy, showcasing the region's commitment to technological advancement [12][13] - The report also mentions the CE certification obtained by the Kando robot from Harbin, which signifies its readiness for the European market, reflecting the growing recognition of Chinese manufacturing in the global arena [11]